William J. Steinbach

Assistant Professor , Division of Pediatric Infectious Diseases, Duke University,USA

Dr. Steinbach is a graduate of University of North Carolina School of Medicine and trained in Pediatrics at Stanford University.  He later completed a pediatric infectious diseases fellowship at Duke University.  He is an associate researcher at the Duke Clinical Research Institute. 

Dr. Steinbach has published over 30 peer-reviewed articles and several book chapters, generally concerning fungal disease and antifungal agents.  He is involved in several clinical trials of newer antifungal agents, including involvement with the NIAID Bacteriology and Mycoses Study Group.  To focus on the issues of fungal disease and treatment in pediatrics, he is also the co-director of the Pediatric Fungal Network.

His basic science interests include in vitro, in vivo, and molecular exploration of A. fumigatus, focusing on mechanisms of pathogenesis as well as optimizing antifungal therapies.  Dr. Steinbach’s clinical interest focuses on invasive aspergillosis diagnosis and management, as well as pediatric fungal infections and the unique characteristics they reveal.  In an effort to unite his basic science and clinical interests, Dr. Steinbach is a co-chairman of the Advances Against Aspergillosis international conference (www.advancesagainstaspergillosis.org). 

Recent key contributions to the literature:

  • Steinbach WJ, Stevens DA.  Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clinical Infectious Diseases  2003;37(suppl 3):S157-87.
  • Blankenship JR, Steinbach WJ, Perfect JR, Heitman J.  Teaching old drugs new tricks: Reincarnating immunosuppressants  as antifungals.  Current Opinion in Investigational Drugs 2003;4:192-199.
  • Steinbach WJ, Perfect JR.  Newer antifungal therapy for emerging fungal pathogens.  International Journal of Infectious Diseases  2003;7:5-10.
  • Steinbach WJStevens DA, Denning DW.  Combination and sequential antifungal therapy for invasive aspergillosis:  Review of published in vitro and in vivo interactions and 6281 cases from 1966-2001.  Clinical Infectious Diseases  2003;37(suppl 3):S188-224.
  • Benjamin DK Jr., Poole C, Steinbach WJ, Rowen JL, Walsh TJ.  Neonatal candidemia and end-organ damage:  A critical appraisal of the literature using meta-analytic techniques. Pediatrics  2003;112:634-640.
  • Benjamin DK Jr., DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark R.  Empirical therapy for neonatal candidemia in very low birthweight infants.  Pediatrics  2003;112:543-547.
  • Steinbach WJ, Marr KA.  Mould infections following hematopoietic stem cell transplantation.  In:  Bowden RA, Ljungman P, Paya CV  (eds).  Transplant Infections, Second Edition, Philadelphia.  Lipppincott Williams and Wilkins.  2003;466-482
  • Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 2004 May;48(5):1664-9.
  • Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004 Jul 15;39(2):192-8.
  • Steinbach WJ, Perfect JR, Schell WA, Walsh TJ, Benjamin DK Jr. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother. 2004 Sep;48(9):3217-25. Review.
  • Steinbach WJ, Benjamin DK Jr, Trasi SA, Miller JL, Schell WA, Zaas AK, Foster WM, Perfect JR. Value of an inhalational model of invasive aspergillosis. Med Mycol. 2004 Oct;42(5):417-25.
  • Steinbach WJ, Singh N, Miller JL, Benjamin DK Jr, Schell WA, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.Antimicrob Agents Chemother. 2004 Dec;48(12):4922-5.
  • Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J. 2005 Apr;24(4):358-64. Review.
  • Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. 2005 Jun;52(3):895-915, viii. Review.
  • Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005 Oct;36(7):621-9.
  • Steinbach WJ. New findings and unique aspects in pediatric aspergillosis. Med Mycol. 2005 May;43 Suppl 1:S261-5.
  • Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord. 2005 Sep;5(3):203-10. Review.
  • Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis.2005 Dec;18(6):484-9.

Contacts:

Division of Pediatric Infectious Diseases
Box 3499
Duke University Medical Center
Durham, NC  27710 USA

Tel +1 (919) 684-6335
Fax +1 (919) 416-9268
Email:  [email protected]